Growth in the Cardiovascular Healthcare Market Driven by Population Aging and an Increase in the Number of Cases
First written in FY2016. 18 of 32 entries say "Restated". Latest entry: 2026-07-30.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「The number of atrial fibrillation ablation procedures increased by approximately 10% year on year, according to our estimate.」
According to our estimate, the number of atrial fibrillation ablation procedures increased by approximately 10% year on year, leading to higher sales volume of related products. - FY2025AdvancedAnnual report
「In EP/ablation, the number of atrial fibrillation ablation procedures increased by approximately 10% year on year.」
With demand for cardiovascular care supported by population aging and other factors, the number of atrial fibrillation ablation procedures during the period increased by approximately 10% year on year. - FY2024-Q3RestatedAnnual report
「We estimate that the number of atrial fibrillation (AF) ablation procedures, which has a particularly significant impact on our performance, increased by 8–9% year on year and continued to grow at a pace exceeding the initial full-year assumption of approximately 6%.」
AF ablation procedure volumes are estimated to have increased by 8–9% year on year, with growth continuing at a pace exceeding the initial full-year assumption of approximately 6%. - FY2024-Q1AdvancedAnnual report
「We estimate that the number of atrial fibrillation (AF) ablation procedures, which has a particularly significant impact on our performance, increased by approximately 9% year on year in the first quarter, exceeding the level assumed at the beginning of the period, namely an approximately 6% increase for the full year.」
AF ablation procedure volumes increased by approximately 9% year on year, exceeding the initial full-year assumption of approximately 6%. - FY2023AdvancedAnnual report
「Against this business environment, we estimate that the number of atrial fibrillation (AF) ablation procedures, which has a particularly significant impact on our performance, increased by approximately 6% year on year during the consolidated fiscal year, remaining broadly in line with the initial plan.」
AF ablation procedure volumes increased by approximately 6% year on year and remained broadly in line with the initial plan. - FY2023-Q3AdvancedAnnual report
「For the cumulative third-quarter consolidated accounting period (April–December), we estimate an increase of approximately 7% year on year, with results remaining broadly in line with the level assumed in the initial plan.」
AF ablation procedure volumes are estimated to have increased by approximately 7% year on year on a cumulative third-quarter basis, remaining broadly in line with the initial plan. - FY2023-Q2AdvancedAnnual report
「We estimate that the number of atrial fibrillation (AF) ablation procedures, which has a particularly significant impact on our performance, increased by 8–9% year on year during the cumulative second-quarter consolidated accounting period, broadly in line with the level assumed in the initial plan.」
AF ablation procedure volumes are estimated to have increased by 8–9% year on year and remained at the level assumed in the initial plan. - FY2023-Q1AdvancedAnnual report
「As a result, the number of cases related to our products increased due to a substantial rise in hospital outpatient visits and the performance of procedures that had been postponed during the period of infection spread. In particular, the number of atrial fibrillation (AF) ablation procedures remained above expectations.」
Case volumes increased against a backdrop of the easing of infections and the performance of postponed procedures, with AF ablation procedure volumes particularly exceeding expectations. - FY2022-Q3RestatedAnnual report
「During the cumulative third-quarter consolidated accounting period, the spread of COVID-19 had a certain impact on case volumes related to our products from April through August. From September onward, the number of infections fell rapidly as vaccination progressed across Japan, and case volumes began to recover.」
While COVID-19 continued to affect case volumes from April through August, case volumes began to recover from September onward as the number of infections declined. - FY2022-Q2RestatedAnnual report
「For EP catheters, sales remained firm, particularly for our one-of-a-kind intracardiac defibrillation catheter, BeeAT (ビート), and esophageal temperature monitoring catheter, Esophastar (エソファスター), as case volumes recovered, resulting in higher revenue than in the year-earlier period.」
Following the recovery in case volumes, revenue from one-of-a-kind products and other products increased in EP catheters. However, the impact of case restrictions remained for some products, and case volumes overall remained in a gradual recovery phase. - FY2022-Q1Case volumes are recovering gradually.Annual report
「Meanwhile, case volumes overall have been recovering gradually as medical institutions implement infection-control measures and work to establish normal medical-care systems.」
While the impact of COVID-19 remains, case volumes overall have been recovering gradually against a backdrop of infection-control measures at medical institutions and the establishment of normal medical-care systems. - FY2021-Q3RestatedAnnual report
「From June 2020, the number of atrial fibrillation ablation procedures began to trend upward and recovered to above the year-earlier level in the second-quarter accounting period. However, partly due to the impact of lower reimbursement prices, revenue for the cumulative third-quarter consolidated accounting period was below the year-earlier level.」
While atrial fibrillation ablation procedure volumes continued to recover from June 2020, cumulative EP/ablation revenue was below the year-earlier level, partly due to the impact of lower reimbursement prices. - FY2021-Q2AdvancedAnnual report
「Although case volumes fell substantially as medical institutions postponed elective procedures with low urgency following the spread of COVID-19, recovery became pronounced in the second-quarter consolidated accounting period as medical facilities from June 2020 onward established systems to provide necessary treatment while implementing infection-control measures.」
After elective procedures declined, case volume recovery became pronounced from June 2020, with some products recording recovery above the year-earlier level in the second-quarter accounting period. - FY2021-Q1Case volumes began to recover from June after a temporary decline.Annual report
「As of the current situation, the lifting of the government's state of emergency declaration on 25 May 2020 and recommendations issued by relevant medical societies regarding the resumption of elective procedures, taking comprehensive account of disease severity and regional infection levels while implementing infection-control measures, have resulted in case volumes trending upward from June 2020.」
While elective procedures declined due to the impact of COVID-19, case volumes began to recover from June 2020 following the lifting of the state of emergency and recommendations from relevant medical societies. - FY2020RestatedAnnual report
「In Japan's medical device market, where we primarily operate, demand has been increasing over the long term due to population aging. In particular, the number of cases requiring treatment in the cardiac and cardiovascular field has continued to trend upward.」
The long-term trends of increasing demand and case volumes driven by population aging are reaffirmed. The decline in case volumes due to COVID-19 at the time is described separately as a risk. - FY2020-Q3RestatedAnnual report
「As the number of atrial fibrillation ablation procedures increased, related products for atrial fibrillation treatment, including our one-of-a-kind products, recorded growth.」
It was stated that the number of atrial fibrillation ablation procedures and related products continued to grow. - FY2020-Q2RestatedAnnual report
「Against a backdrop of increasing atrial fibrillation ablation procedures, related products for atrial fibrillation treatment, including our one-of-a-kind products, recorded growth.」
The number of atrial fibrillation ablation procedures and related products continued to grow. - FY2020-Q1RestatedAnnual report
「In addition, in EP/ablation, related products for atrial fibrillation treatment, including our one-of-a-kind products, continued to grow against a backdrop of increasing atrial fibrillation ablation procedures.」
The continued increase in atrial fibrillation ablation procedures and growth in related products are again described. - FY2019-Q3RestatedAnnual report
「Meanwhile, in EP/ablation, related products for atrial fibrillation treatment recorded growth as the number of atrial fibrillation ablation procedures increased.」
The number of atrial fibrillation ablation procedures and related products continued to grow. - FY2019-Q2RestatedAnnual report
「In EP/ablation, related products for atrial fibrillation treatment recorded growth as the number of atrial fibrillation ablation procedures continued to increase.」
The continued increase in atrial fibrillation ablation procedures led to higher sales of related products. - FY2019-Q1RestatedAnnual report
「In rhythm devices, revenue declined due to a substantial reduction in reimbursement prices for cardiac pacemakers. In EP/ablation, however, related products for atrial fibrillation treatment, including our one-of-a-kind products, continued to grow as the number of atrial fibrillation ablation procedures increased.」
The continued increase in atrial fibrillation ablation procedures led to higher sales of related products. - FY2018RestatedAnnual report
「In the cardiac and cardiovascular field, our core business area, the number of cases has continued to increase at a high level due to factors including the increase in diseases associated with population aging and advances in medical devices that have made it possible to treat cases that were previously difficult to treat.」
The number of cases in the cardiovascular field has continued to increase at a high level against a backdrop of population aging and advances in medical devices. - FY2018-Q3RestatedAnnual report
「For EP catheters, the number of atrial fibrillation ablation procedures continued to increase, driving higher sales volume, particularly for our one-of-a-kind intracardiac defibrillation catheter, BeeAT (ビート).」
The continued increase in atrial fibrillation ablation procedures is driving higher sales volume of related products. - FY2018-Q2RestatedAnnual report
「In EP/ablation, where we primarily handle our own products, related products for atrial fibrillation treatment, including our one-of-a-kind products, recorded growth as the number of atrial fibrillation ablation procedures continued to increase.」
The number of atrial fibrillation ablation procedures continued to increase, leading to growth in related products. - FY2018-Q1AdvancedAnnual report
「Against a backdrop of continued strong growth in the number of atrial fibrillation ablation procedures, related products for atrial fibrillation treatment, including our one-of-a-kind products, recorded growth.」
The number of atrial fibrillation ablation procedures continued to grow strongly, leading to higher sales of related products. - FY2017RestatedAnnual report
「For the medical devices handled by our Group, primarily in the cardiovascular field, the number of cases has been trending upward against a backdrop of population aging. In addition, advances in various technologies have led to the development of new medical devices, expanding the range of treatable cases, creating new markets and driving continued market expansion.」
The outlook for the expansion of cases and treatable conditions, as well as market growth, driven by population aging and technological advances, is described again. - FY2017-Q3RestatedAnnual report
「The number of cases involving cardiovascular diseases continues to rise due to population aging and the expansion of eligible cases resulting from advances in medical devices, and sales volumes of medical devices have consequently continued to trend upward.」
Against a backdrop of population aging and the expansion of eligible cases, the number of cardiovascular disease cases and medical device sales volume have continued to trend upward. - FY2017-Q2RestatedAnnual report
「The number of cases involving cardiovascular diseases continues to rise due to population aging and the expansion of eligible cases resulting from advances in medical devices, and sales volumes of medical devices have consequently continued to trend upward.」
Against a backdrop of population aging and advances in medical devices, the number of cardiovascular disease cases and sales volume of related products have continued to trend upward as the number of cases eligible for treatment has expanded. - FY2017-Q1AdvancedAnnual report
「Against a backdrop of atrial fibrillation ablation cases increasing beyond expectations, sales grew for products related to atrial fibrillation treatment, including one-of-a-kind products.」
The company stated that the number of atrial fibrillation ablation cases had increased beyond expectations. - FY2016First statedAnnual report
「While the number of diseases is trending upward due to population aging and other factors, the government revises reimbursement prices, the official prices of medical devices, every 2 years and tends to lower them in an effort to contain the steadily rising cost of healthcare.」
The company described a market structure in which demand is expanding as the number of diseases and cases increases, while prices are being reduced to contain healthcare costs.